Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Now, 68% of users are taking GLP-1s specifically to lose weight, opening them up to a much wider audience
S1473-3099(25)00224-5
Further research is warranted to determine whether GLP-1 RAs are being prescribed primarily for metabolic indications in this group or whether clinical use is expanding to include PCOS-related symptoms and outcomes
For perimenopausal women, weight management becomes particularly challenging due to hormonal fluctuations that affect metabolism, appetite regulation, and body composition
A., Wang, H
Trial Structure Duration: 48 weeks of treatment Participants: 338 adults randomized 2:1:1:1:1:2:2 to placebo or retatrutide groups Doses tested: 1mg, 4mg, 8mg, 12mg (all with slow titration from 2mg starting dose) Lifestyle intervention: All participants received counseling on diet (500 kcal/day deficit) and exercise (150 min/week) Primary endpoint: Percent weight change at 24 weeks Key secondary endpoints: Weight change at 48 weeks, proportion achieving 5%, 10%, 15% loss The trial used a slow titration protocol to minimize side effects: all groups except the 1mg dose started at 2mg weekly and escalated every 4 weeks
US$ 20.20
US$ 20.89
US$ 20.83
US$ 24.27
US$ 20.78
US$ 22.02
US$ 21.69
US$ 20.69
US$ 24.28
US$ 21.78
